Effects of Turmeric (Curcuma longa L.) on Blood Glucose and Lipid Metabolism Functional Improvement in STZ-induced Diabetic rats

2019 ◽  
Vol 28 (5) ◽  
pp. 485-494
Author(s):  
Da-Young Oh ◽  
Dong-Soo Kang ◽  
Young-Geun Lee ◽  
Han-Soo Kim
Keyword(s):  
Lipid Metabolism ◽  
Blood Glucose ◽  
Curcuma Longa ◽  
Diabetic Rats ◽  
Functional Improvement ◽  
Glucose And Lipid Metabolism

scholarly journals EFFECT OF DURUM WHEAT BRAN ON GLUCOSE AND LIPID METABOLISM IN DIABETIC RATS.

2020 ◽  
Vol 10 (2-s) ◽  
pp. 30-34
Author(s):  
Louiza Tarfaoui ◽  
Noreddine Menadi ◽  
Samira Meziani ◽  
Mohamed Zairi ◽  
Iméne Bekhaled ◽  
...  
Keyword(s):  
Lipid Metabolism ◽  
Blood Glucose ◽  
Wheat Bran ◽  
Serum Lipid ◽  
Control Diet ◽  
Diabetic Rats ◽  
Diet Group ◽  
Experimental Diet ◽  
Glucose And Lipid Metabolism ◽  
Experimental Group

Introduction.Durum wheat bran is obtained from wheat milling, it’s considered as an excellent source of insoluble dietary fibre. Objective. The aim of this paper was to evaluate the effect of wheat bran (WB)  on glucose and lipid metabolism in normal and diabetic rats. Materials and Methods. Twenty-four female rats of "Wistar" were divided into four groups each containing six rats. The first group (NCR) was fed by a control diet while the second group (NCRE) was fed by the experimental diet based on durum wheat bran. For the third and fourth group after streptozotocin (STZ) injection, they were fed by a control diet (DCR) and experimental diet (DRE) respectively. The Blood Glucose (g/L) and weight (g) of these groups was measured at the end of each week for a period of four weeks, the serum lipid parameters in the fasting condition, such as TC, TG, LDL-C and HDL-C were evaluated at the end of the experience. Results. WB was high in dietary fibre (41%). The results show a significant decrease in blood glucose ( p<0.04)  and body weight ( p<0.05 ) in DRE group compared to DCR group  and non-diabetic groups. No significant difference was observed for cholesterol and triglyceride levels, a difference of p<0.05 for HDL-C was observed between the diabetic experimental diet group and the non-diabetic control diet group. For LDL-C, the difference was observed between the diabetic experimental group and the non-diabetic experimental group (p<0.001). Conclusion Our results indicated that WB exerting a glycemic and a serum lipid regulation effect in experimental diabetic rats.

Effect of Fomitopsis pinicola extract on blood glucose and lipid metabolism in diabetic rats

2009 ◽  
Vol 26 (6) ◽  
pp. 1696-1699 ◽  
Author(s):  
Wol-Suk Cha ◽  
Ji-Lu Ding ◽  
Hyun-Jae Shin ◽  
Jong-Soo Kim ◽  
Youn-Soon Kim ◽  
...  
Keyword(s):  
Lipid Metabolism ◽  
Blood Glucose ◽  
Diabetic Rats ◽  
Fomitopsis Pinicola ◽  
Glucose And Lipid Metabolism

Improvement of glucose and lipid metabolism in diabetic rats treated with molybdate

1996 ◽  
Vol 270 (2) ◽  
pp. E344-E352 ◽  
Author(s):  
A. T. Ozcelikay ◽  
D. J. Becker ◽  
L. N. Ongemba ◽  
A. M. Pottier ◽  
J. C. Henquin ◽  
...  
Keyword(s):  
Lipid Metabolism ◽  
Phosphoenolpyruvate Carboxykinase ◽  
Fatty Acid Synthase ◽  
Diabetic Rats ◽  
Nonesterified Fatty Acids ◽  
Insulin Resistant ◽  
Hepatic Glucose Metabolism ◽  
Glucose And Lipid Metabolism ◽  
Glycogen Stores

Molybdenum mimics certain insulin actions in vitro. We have investigated the effects of oral administration of Na2MoO4 (Mo) for 8 wk on carbohydrate and lipid metabolism in streptozotocin-diabetic rats. Mo decreased hyperglycemia and glucosuria by 75% and corrected the elevation of plasma nonesterified fatty acids. Tolerance to glucose loads was improved, and glycogen stores were replenished. These effects were not due to a rise of insulinemia. In liver, Mo restored the blunted mRNA and activity of glucokinase and pyruvate kinase and decreased to normal phosphoenolpyruvate carboxykinase values. Finally, Mo totally reversed the low expression and activity of acetyl-CoA carboxylase and fatty acid synthase in liver, but not in white adipose tissue. In conclusion, Mo exerts a marked blood glucose-lowering effect in diabetic rats by an insulin-like action. This effect results in part from a restoration of hepatic glucose metabolism and is associated with a tissue-specific correction of lipogenic enzyme gene expression, both processes being essentially mediated by reversal of impaired pretranslational regulatory mechanisms. These observations raise new therapeutic perspectives in diabetes, particularly in the insulin-resistant condition.

scholarly journals Effects of Marine Drug Propylene Glycol Alginate Sodium Sulfate on Glucose and Lipid Metabolism in Mice

2021 ◽  
Vol 58 (2) ◽  
pp. 150-154
Author(s):  
Haiyue Liang ◽  
Qun Liu ◽  
Yonghong Xiu
Keyword(s):  
Lipid Metabolism ◽  
Blood Glucose ◽  
Sodium Sulfate ◽  
Glycosylated Hemoglobin ◽  
Fasting Blood Glucose ◽  
Density Lipoprotein ◽  
Control Group ◽  
Distilled Water ◽  
Glucose And Lipid Metabolism ◽  
Propylene Glycol Alginate

Previous studies have shown that marine drug propylene glycol alginate sodium sulfate (PSS) plays important roles in human diseases. This study mainly explored the effects of PSS on hyperglycemia and hyperlipidemia in diabetic db/db mouse models. The db/db mice were randomly divided into 5 groups (n=12), which were model control group (distilled water), positive control group (metformin), PSS low, medium, and high dose groups (PSS25, PSS50, PSS100) and normal control group (C57/BL, distilled water). The mice in each group had free diet and water for 90 days. During the experiment, food intake was recorded every day and body weight was recorded weekly. In addition, fasting blood glucose and glycosylated hemoglobin levels were measured regularly. Finally, the contents of triglyceride (TG), low-density lipoprotein (LDL-c), high-density lipoprotein (HDL-c) and total cholesterol (TC) in the serum of mice were determined. PSS can significantly reduce fasting blood glucose and glycosylated hemoglobin levels in db/db mice, and improve insulin sensitivity. Moreover, PSS can reduce the fat accumulation of db/db mice and significantly improve the blood lipid level of db/db mice. PSS can significantly improve the symptoms of glucose and lipid metabolism disorders in db/db mice.

scholarly journals Efficacy and Safety of Zhenyuan Capsule for Coronary Heart Disease with Abnormal Glucose and Lipid Metabolism: Study Protocol for a Randomized, Double-Blind, Parallel-Controlled, Multicenter Clinical Trial

2018 ◽  
Vol 2018 ◽  
pp. 1-7 ◽  
Author(s):  
Yu Qiao ◽  
Jingchun Zhang ◽  
Yue Liu ◽  
Zhiqi Liang ◽  
Yuhua Wang ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Lipid Metabolism ◽  
Blood Glucose ◽  
Glycosylated Hemoglobin ◽  
Postprandial Blood Glucose ◽  
Common Disease ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Glucose And Lipid Metabolism

Background. Coronary heart disease (CHD) and abnormal glucose and lipid metabolism are closely associated and generally coexist. The Qi and Yin deficiency syndrome is a common disease pattern encountered in traditional Chinese medicine. We designed a protocol to determine the effectiveness and safety of Zhenyuan capsules for CHD with abnormal glucose and lipid metabolism. Methods. This multicenter, randomized, double-blind, parallel-controlled trial was designed in accordance with the CONSORT. We will recruit 200 eligible male patients aged 45–75 years from three participating centers and randomly assign them to treatment and control groups (1 : 1). The primary indicators are glycosylated hemoglobin, fasting blood glucose, 2-hour postprandial blood glucose, and triglyceride levels. The secondary indicators are the Seattle Angina Questionnaire, TCM symptom indicators, ultrasonic cardiography finding, coagulation indicator, and P-selectin level. Measurements will be performed at baseline (T0), the end of the run-in period (T1), and weeks 4 (T2), 8 (T3), and 12 (T4) of the treatment period. Adverse events will be monitored during the trial. Discussion. This study aims to evaluate the efficacy and safety of Zhenyuan capsules in patients with CHD and abnormal glucose and lipid metabolism. The results will provide critical evidence of the usefulness of the Chinese herbal medicine for CHD with abnormal glucose and lipid metabolism. Trial Registration. This trial is registered with the Chinese Clinical Trials Registry, with identifier number ChiCTR-TRC-14004639, May 4, 2014.

Sign in / Sign up

Export Citation Format

Share Document